Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Pediatrics. Author manuscript; available in PMC 2010 February 10.
Published in final edited form as:
PMCID: PMC2819143

Outcomes of Safety and Effectiveness in a Multicenter Randomized, Controlled Trial of Whole-Body Hypothermia for Neonatal Hypoxic-Ischemic Encephalopathy



Whole-body hypothermia reduced the frequency of death or moderate/severe disabilities in neonates with hypoxic-ischemic encephalopathy in a randomized, controlled multicenter trial.


Our goal was to evaluate outcomes of safety and effectiveness of hypothermia in infants up to 18 to 22 months of age.


A priori outcomes were evaluated between hypothermia (n = 102) and control (n = 106) groups.


Encephalopathy attributable to causes other than hypoxia-ischemia at birth was not noted. Inotropic support (hypothermia, 59% of infants; control, 56% of infants) was similar during the 72-hour study intervention period in both groups. Need for blood transfusions (hypothermia, 24%; control, 24%), platelet transfusions (hypothermia, 20%; control, 12%), and volume expanders (hypothermia, 54%; control, 49%) was similar in the 2 groups. Among infants with persistent pulmonary hypertension (hypothermia, 25%; control, 22%), nitric-oxide use (hypothermia, 68%; control, 57%) and placement on extracorporeal membrane oxygenation (hypothermia, 4%; control, 9%) was similar between the 2 groups. Non–central nervous system organ dysfunctions occurred with similar frequency in the hypothermia (74%) and control (73%) groups. Rehospitalization occurred among 27% of the infants in the hypothermia group and 42% of infants in the control group. At 18 months, the hypothermia group had 24 deaths, 19 severe disabilities, and 2 moderate disabilities, whereas the control group had 38 deaths, 25 severe disabilities, and 1 moderate disability. Growth parameters were similar between survivors. No adverse outcomes were noted among infants receiving hypothermia with transient reduction of temperature below a target of 33.5°C at initiation of cooling. There was a trend in reduction of frequency of all outcomes in the hypothermia group compared with the control group in both moderate and severe encephalopathy categories.


Although not powered to test these secondary outcomes, whole-body hypothermia in infants with encephalopathy was safe and was associated with a consistent trend for decreasing frequency of each of the components of disability.

Keywords: hypoxic-ischemic encephalopathy, whole-body hypothermia, safety, effectiveness

Among term infants, hypoxic-ischemic encephalopathy (HIE) caused by acute perinatal asphyxia remains an important cause of neurodevelopmental deficits in childhood.1,2 Currently, there is increasing evidence that mild or moderate brain hypothermia reduces brain injury caused by hypoxia and ischemia.37 We have demonstrated that whole-body hypothermia reduces the risk of death or disability in infants with moderate or severe HIE.6 However, enthusiasm regarding the beneficial effects of hypothermia has been tempered by concerns of safety. These concerns have focused on potential complications involving coagulation and immunologic defects, cardiovascular and pulmonary compromise, metabolic adverse effects, and hematologic effects.813

In the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network's randomized, controlled trial of whole-body cooling for neonatal HIE, very few adverse events were noted during the 72-hour intervention period.6 We noted 2 cases of cardiac arrhythmia (1 case in the hypothermia group and 1 in the control group), 2 cases of persistent acidosis (in the hypothermia group), 5 cases of bleeding (3 infants in the hypothermia group and 2 infants in the control group), skin changes (in 4 cooled infants), and 24 deaths (13 in the hypothermia group and 11 in the control group). The objective of the present study was to report other secondary outcomes of safety and effectiveness of whole-body cooling in the trial participants up to 18 to 22 months of age. The trial was not designed to assess harm or adverse events; we acknowledge the limited power to assess adverse events that are infrequent.

Patients and Methods

Data from the NICHD Neonatal Research Network whole-body hypothermia trial were used for this analysis.6 Neonates with either moderate or severe encephalopathy based on a modified Sarnat scoring14 were randomly assigned to whole-body cooling or usual care. Total-body cooling to a temperature of 33.5°C was maintained for 72 hours in the cooled group followed by rewarming at 0.5°C every hour for 6 hours. The primary outcome of the study was either death or moderate or severe disability at 18 to 22 months of age. Severe disability was defined as a Mental Developmental Index (MDI) on the Bayley Scales of Infant Development II15 of <70 or Gross Motor Functional Classification System (GMFCS)16 rating of 3 to 5 or bilateral blindness or deafness requiring amplification. Moderate disability included an MDI of 70 to 84 and a GMFCS level of 2, a hearing deficit without amplification, or a seizure disorder requiring anticonvulsive therapy at 18 months of age.

To monitor for potential adverse effects of hypothermia, data collected during the 72-hour intervention and rewarming period included blood pressure support and transfusion needs,10 as well as effects of anticonvulsant and analgesic/sedation medications12,13 on target temperature. In addition, changes in oxygen requirements among those infants diagnosed with persistent pulmonary hypertension of the newborn (PPHN) were collected during the study intervention and rewarming period.

During the hospital stay, our evaluation also included a detailed review of medical charts to identify other potential causes of encephalopathy aside from hypoxia-ischemia that have been noted by other investigators, including infectious, metabolic, and neuromuscular causes or major congenital anomalies.17,18 In addition, we documented the frequency of multiorgan injury other than the central nervous system (CNS).2,17,19 Pulmonary involvement included meconium-aspiration syndrome, PPHN (including use of inhaled nitric oxide and placement on extracorporeal membrane oxygenation [ECMO]), chronic lung disease, and/or pulmonary hemorrhage. Cardiac involvement included cardiomegaly, cardiac failure and cardiac dysfunction indicated by echocardiography, cardiac ischemia indicated by electrocardiography, or elevated enzyme levels, hypotension, hypertension, and/or arrhythmia. Renal involvement included oliguria, anuria, and/or dialysis. Gastrointestinal involvement included hepatic dysfunction or necrotizing enterocolitis. Infectious diseases included bloodstream infection, meningitis, or encephalitis. Hematologic dysfunction included disseminated intravascular coagulopathy, and metabolic dysfunction included hypoglycemia, hypocalcemia, and/or hypomagnesemia.

After NICU discharge, data were collected on hospitalizations, growth parameters, and neurologic and developmental outcome (as defined above) at 18 to 22 months of age. Microcephaly was defined as a head circumference below the 10 percentile.

Dichotomous data were compared by using Fisher's exact test, and continuous data were analyzed by linear regression analysis. Relative risks and 95% confidence intervals were obtained by using the Mantel-Haenszel test, with adjustments accounting for center differences. A significance level of <.05 was used for comparisons between the 2 treatment groups.


Hospital Stay in the NICU

The diagnosis of encephalopathy at enrollment was confirmed by review of status at death or NICU discharge for all study participants. None of the study infants were diagnosed to have malformations or metabolic or neuromuscular disorders as a cause of encephalopathy despite routine screening with cranial sonography and MRI and intensive assessments before NICU discharge.

In the hypothermia group, the esophageal temperature was noted to be transiently reduced with the initiation of cooling to below the target temperature of 33.5°C.6 The mean time to initially surpass 33.5°C was 0.9 ± 0.5 hours (range: 0.25–3.50 hours). The mean maximum overshoot below the target temperature was −1.4°C ± 0.6°C (range: 0.0°C−4.1°C). The mean time to maximum overshoot below the target temperature was 1.3 ± 1.0 hours (range: 0.25–8.00 hours). The mean time to equilibration after overshoot (defined as within 0.1°C of target temperature) was 1.9 ± 3.6 hours (range: 0.0–21.0 hours) after initiation of cooling. We noted some unexpected findings: (1) 1 infant never achieved equilibration, and (2) there were 40 temperatures recorded to be <32.0°C after the initial overshoot. There were 27 infants with temperatures of <32.0°C after the initial overshoot and 10 infants who had temperatures of <32.0°C after equilibration.

During the study intervention period, among the infants who were cooled, there were no significant differences in the median or first- and third-quartile esophageal temperatures among infants who received anticonvulsants and those who did not receive these medications. At 24, 48, and 72 hours, the mean esophageal temperatures were, respectively, 33.4°C, 33.3°C, and 33.4°C among those who received anticonvulsants and 33.3°C, 33.4°C, and 33.3°C among those who did not receive these medications. Similar esophageal temperatures were recorded at 24, 48, and 72 hours among infants who received sedatives and those who did not receive sedatives. In the hypothermia group at the end of the 72-hour intervention of cooling, the mean esophageal temperature was 33.4°C ± 0.4°C. At 76 hours of study intervention, during the rewarming phase, the mean esophageal temperature was 35.3°C ± 0.6°C. At the end of the rewarming phase, at 78 hours of study intervention, the mean esophageal temperature was 35.9°C ± 0.8°C. Because esophageal temperatures were not recorded every 4 hours after 78 hours, information is lacking as to when infants in the hypothermia group reached “normal” esophageal temperatures.

Events that occurred and therapies that were provided during the NICU stay are noted in Table 1. The use of inotropic agents, volume expanders, blood transfusions, or platelet transfusions during the study intervention period was comparable among infants in the hypothermia and control groups. The platelet count at 72 hours of study intervention was a median of 132 in the hypothermia group (quartile 1 to 3: 77–194) and 129 in the control group (quartile 1 to 3: 78–195). The minimum platelet count during the 72-hour period was a median of 139 (quartile 1 to 3: 62–211) and 156 (quartile 1 to 3: 87–202) in the hypothermia and control groups, respectively. The number of infants with clinical seizures at baseline and at 48 and 72 hours of study intervention were similar in the hypothermia group compared with the control group (Table 1). At 24 hours of study intervention, fewer infants in the hypothermia group had seizures as compared with those in the control group.

Table 1
Acute Outcome in the NICU

The number of infants who had any of the 7 organ systems (pulmonary, cardiac, renal, gastrointestinal, infectious, hematologic, and metabolic) involved, in addition to the CNS, was 76 infants in the hypothermia group and 77 in the control group. One-organ-system involvement, in addition to the CNS, was noted among 25 infants in the hypothermia group and 36 in the control group; 2-organ-system involvement was noted among 23 in the hypothermia group and 13 in the control group; and 3-organ-system involvement was noted among 14 in the hypothermia group and 15 in the control group. Seven infants in the hypothermia group had 4 systems involved compared with 10 infants in the control group, and >4-system involvement occurred in 7 infants in the hypothermia group compared with 3 in the control group.

The number of infants diagnosed with PPHN was 25 in the hypothermia group and 23 in the control group (Table 1). The mean fraction of inspired oxygen (FiO2) requirement among infants with PPHN during the 72-hour intervention period was similar between groups; at 24, 48, and 72 hours, the requirement was, respectively, 0.97, 0.97, and 0.94 in the hypothermia group and 0.90, 0.65, and 0.53 in the control group. The number of infants who received inhaled nitric oxide or who were placed on ECMO was also comparable between the 2 groups.

Nineteen infants had major surgery before NICU discharge; these surgeries included ECMO cannulation in 1 infant in the hypothermia group and 2 in the control group; other procedures among the 16 infants are listed in Table 1.

Rehospitalization and Growth Parameters at 18 Months of Age

The number of infants who were rehospitalized was comparable in both the hypothermia and control groups (Table 2). Growth parameters were also comparable in infants in the hypothermia and control groups. The number of infants who had microcephaly was 22 (30%) of 74 in the hypothermia group and 17 (27%) of 62 in the control group (P = .77); microcephaly noted was observed only at the 18-month visit, because the growth parameters at birth were in the normal range.6

Table 2
Status at 18 Months of Age

Death or Disabilities at 18 Months of Age

The study's primary outcome was death or moderate or severe disabilities at 18 months of age (Table 3). There were 24 deaths in the hypothermia group and 38 in the control group, and there were 19 infants in the hypothermia group diagnosed with a severe disability, whereas 25 infants in the control group were noted to have a severe disability. Severe disabilities among these 44 infants included 34 with an MDI of <70 and at least 1 of the other components of severe disability, 9 infants with only an MDI of <70, and 1 infant with an MDI of 70 to 84 with deafness. Only 3 infants had a moderate disability; 2 infants in the hypothermia group (1 infant with an MDI of 70–84 and hearing impairment with no amplification and the other with an MDI of 70–84 and a GMFCS level 2) compared with 1 infant in the control group (MDI of 70–84 and seizure disorder at 18 months). Among the 29 infants with quadriplegia, additional neurologic findings included truncal hypotonia (n = 6), truncal hypotonia with athetosis (2 infants), generalized hypotonia (1 infant), generalized hypertonia (1 infant), athetosis (1 infant), and dystonia (1 infant).

Table 3
Death and Disability at 18 Months

Relationship of Severity of Encephalopathy at Randomization to Outcome at 18 Months of Age

Data were missing from the 3 infants in the control group (lost to follow-up) and 1 infant in the hypothermia group (this infant qualified for study eligibility with seizures at <6 hours of age but did not have a neurologic examination at randomization) (Table 3). Although the study was not powered to evaluate death or disability separately among infants designated as having moderate encephalopathy and severe encephalopathy, there was a consistent trend in the decrease in frequency of disability in the infants in the hypothermia group compared with those in the control group.

Association of Variables Evaluated for Safety with Outcome at 18 to 22 Months of Age

Among the infants in the hypothermia group, the mean time to maximum overshoot at the onset of cooling was not related to the primary outcome (1.2 ± 0.5 hours in infants with the primary outcome compared with 1.4 ± 1.3 hours among those without the primary outcome [P = .23]). The mean time to equilibration of target temperature after maximum overshoot also did not impact outcome (2.3 ± 4.1 vs 1.5 ± 3.2 hours with primary outcomes versus without the primary outcome, respectively [P = .29]). Last, the outcome of infants in the hypothermia group with an esophageal temperature recorded below 33.5°C was not related to the primary outcome: those with the primary outcome spent 45 ± 21 hours below 33.5°C, whereas those without the primary outcome spent 51 ± 16 hours below 33.5°C (P = not significant).

The presence of non-CNS organ dysfunction during the neonatal course (in addition to HIE) was related to the primary outcome. The risk varied with the organ system involved: pulmonary involvement (n = 63) was associated with primary outcome in 65% vs 48% with no pulmonary involvement (P = .02). Renal involvement (n = 44) was associated with a primary outcome in 68% vs 49% with no renal involvement (P = .03); there was a trend for cardiac involvement (n = 91) to be associated with the primary outcome in 60% vs 48% with no cardiac involvement (P = .09). Gastrointestinal, hematologic, or metabolic problems, in addition to HIE, did not increase the risk of the primary outcome.

Among the outcomes assessed at follow-up, the presence of microcephaly was not associated with treatment group; however, microcephaly was significantly associated with primary outcome in both groups. In the hypothermia group, 82% of the infants with microcephaly had the primary outcome present compared with 6% without microcephaly, whereas in the control group, 71% with microcephaly had the primary outcome present compared with 27% without microcephaly (all P < .01).


The data we have presented support the safety of whole-body hypothermia for infants with moderate and severe HIE when adhering to strict entry criteria and cooling initiated within 6 hours of age at participating centers. A relative risk of < 1.0 was identified for death and each of the components of severe disability at 18 to 22 months of age. Our data support the safety of hypothermia during the period of cooling as well as during the NICU hospitalization and follow-up through 18 to 22 months of age.

We did not find any decrease in platelet counts or increase in bleeding episodes among infants in our study. Our protocol did not include investigations to evaluate the coagulation profile or blood viscosity status for all participants. Eicher et al10 noted a low platelet count on each day of cooling with an increase in platelet count on the fourth day. However, no clinical manifestations of coagulopathy were found in that study. In the same trial, treatment was used for hypotension among more infants in the cooled group as compared with the control group. It should be noted that 77% of the infants who were enrolled in the Eicher et al trial had severe encephalopathy at the time of enrollment, and 75% of the infants were outborn. In the other 2 larger randomized, controlled trials, the CoolCap study and the NICHD trial, infants with severe encephalopathy comprised ~33% of enrolled infants and fewer were outborn compared with the Eicher et al trial.4,6

The cardiovascular complications associated with hypothermia in adult cooling trials include pulmonary vasoconstriction, sinus bradycardia, cardiac arrhythmia, and increased blood viscosity.2022 All the neonatal cooling studies have documented sinus bradycardia during the period of cooling without significant cardiovascular effects.47,10 A recent study has documented that in term neonates undergoing hypothermia for HIE, cardiac output and stroke volume are both lower during the period of hypothermia and slowly increase to baseline during the rewarming phase.23 Investigators have also noted that the QT interval can be prolonged with cooling, and hypotension can occur during cooling.24 We have reported previously that there was no difference between systolic and diastolic blood pressure throughout the period of study intervention.6 In this study, we observed similar use of inotropic agents, blood transfusions, and volume expanders during the study period in the 2 groups. The number of infants who required aggressive therapy for PPHN, including inhaled nitric oxide or ECMO, was not higher among infants who were cooled as compared with control infants in our study. In addition, we did not find that administration of anticonvulsant drugs or analgesics/sedatives produced decreases in temperature during cooling as noted by others.12,13 This lack of influence of medications on esophageal temperature may be a result of the cooling system that was servo-controlled and adjusted cooling to maintain a stable temperature.

Hypothermia has profound immunosuppressive and antiinflammatory effects and in adults is associated with increased risk of infectious complications such as pneumonia and bloodstream infection.2022 We did not find an increase in the rate of bloodstream infection among the infants who were cooled, either during the intervention period or during the entire hospitalization course.

In this study, we found that fewer infants in the hypothermia group had clinical seizures after 24 hours of study intervention as compared with the control group. We are unable to explain this finding, which is different from the findings of Eicher et al.10 Video electroencephalography recording was not a part of the protocol; hence, it is likely that the incidence of seizures was underestimated. Recent preclinical studies have noted that hypothermia delays onset of seizures and reduces seizure incidence and severity, and there have been no experimental data to suggest that hypothermia increases seizures.25


The safety of whole-body cooling initiated within 6 hours of age to a depth of 33.5°C for 72 hours' duration has been demonstrated. However, the rate of death and disability continues to be high, even with this safe method of cooling. In the NICHD trial, hypothermia to 33.5°C for 72 hours reduced death and disability of infants with moderate HIE to 32% and severe HIE to 72%. Preclinical data suggest that cooling earlier and to a greater depth may be more effective.8,26,27 However, the safety of cooling during transport of infants to a referral center has not been evaluated yet.

At the present time, no pharmacologic agent is ready for clinical trials in neonates with HIE.28 The method of cooling we have described needs to be improved with no/minimal overshoot and rapid achievement and stability of the target temperature. The observation of unexplained transient decreases in esophageal temperature to <32°C during cooling using servo control emphasizes the need to have trained staff available who are well versed with all potential technical problems associated with a cooling regimen. It is also apparent that monitoring of temperatures needs to be continued beyond 6 hours after cessation of cooling and initiation of rewarming, because it is unclear when normal temperature is achieved. We suggest that clinical trials in the future be focused on defining the optimal degree and duration of cooling and rewarming strategies as neuroprotection for neonatal encephalopathy.

The Hypothermia Study Group

Case Western Reserve University, Rainbow Children's Hospital: Avroy A. Fanaroff, MD (principal investigator), Michele C. Walsh, MD (co–principal investigator), Nancy Newman, BA, RN (study coordinator), DeeAnne Wilson-Costello, MD (follow-up principal investigator), and Bonnie Siner, RN (follow-up coordinator); Brown University Women & Infant's Hospital: William Oh, MD (principal investigator), Angelita Hensman, BSN, RNC (study coordinator), Betty Vohr, MD (follow-up principal investigator), and Lucy Noel, RN (follow-up coordinator); Duke University: C. Michael Cotten, MD (principal investigator), Kathy Auten, BS (study coordinator), Ricki Goldstein, MD (follow-up principal investigator), and Melody Lohmeyer, RN (follow-up coordinator); Emory University, Grady Memorial Hospital and Crawford Long Hospital: Barbara J. Stoll, MD (principal investigator), Lucky Jain, MD (co–principal investigator), and Ellen Hale, RN, BS (study coordinator); Indiana University, Riley Hospital for Children and Methodist Hospital: James A. Lemons, MD (principal investigator), Diana Dawn Appel, RN, BSN, and Lucy Miller, RN, BSN (study coordinators), Anna Dusick, MD (follow-up principal investigator), and Leslie Richard, RN (follow-up coordinator); Stanford University: David K. Stevenson, MD (principal investigator), Krisa VanMeurs, MD (co– principal investigator), M. Bethany Ball, BS, CCRC (study coordinator), and Susan R. Hintz, MD (follow-up principal investigator); University of Alabama at Birmingham, University Hospital-UAB: Waldemar A. Carlo, MD (principal investigator), Monica Collins, RN, BSN, and Shirley Cosby, RN, BSN (study coordinator), Myriam Peralta-Carcelen, MD (follow-up principal investigator), and Vivien Phillips, RN, BSN (follow-up coordinator); University of Cincinnati, University Hospital, Cincinnati Children's Hospital Medical Center: Edward F. Donovan, MD (principal investigator), Cathy Grisby, BSN, Barb Alexander, RN, Jody Shively, RN, and Holly Mincey, RN (study coordinators), Jean Steichen, MD (follow-up principal investigator), and Teresa Gratton, PA (follow-up coordinator); University of California-San Diego, UCSD Medical Center and Sharp Mary Birch Hospital for Women: Neil N. Finer, MD (principal investigator), David Kaegi, MD (co–principal investigator), Chris Henderson, CRTT, Wade Rich, RRT-NPS, and Kathy Arnell, RN (study coordinators), Yvonne E. Vaucher, MD, MPH (follow-up principal investigator), and Martha Fuller, RN, MSN (follow-up coordinator); University of Miami: Shahnaz Duara, MD (principal investigator), Ruth Everett, BSN (study coordinator), and Charles R. Bauer, MD (follow-up principal investigator); University of Rochester, Golisano Children's Hospital at Strong: Ronnie Guillet, MD, PhD (principal investigator), Linda Reubens, RN (study coordinator), Gary Myers, MD (follow-up principal investigator), and Diane Hust, RN (follow-up coordinator); University of Texas Southwestern Medical Center at Dallas, Parkland Hospital: Abbot R. Laptook, MD (principal investigator), Susie Madison, RN, Gay Hensley, RN, and Nancy Miller, RN (study coordinators), Roy Heyne, MD, and Sue Broyles, MD (follow-up principal investigators), and Jackie Hickman, RN (follow-up coordinator); University of Texas, Memorial Hermann Children's Hospital: Jon E. Tyson, MD, MPH (principal investigator), Georgia McDavid, RN, Esther G. Akpa, RN, BSN, Claudia Y. Franco, RN, BNS, MSN, NNP, Patty A. Cluff, RN, and Anna E. Lis, RN, BSN (study coordinators), Brenda H. Morris, MD, and Pamela J. Bradt, MD, MPH (follow-up principal investigators); Wayne State University, Hutzel Women's Hospital & Children's Hospital of Michigan: Seetha Shankaran, MD (principal investigator), Rebecca Bara, RN, BSN, and Geraldine Muran, RN, BSN (study coordinators), Yvette Johnson, MD (follow-up principal investigator), and Debbie Kennedy, RN (follow-up coordinator); and Yale University, New Haven Children's Hospital: Richard A. Ehrenkranz, MD (principal investigator), Patricia Gettner, RN (study coordinator), and Elaine Romano, RN (follow-up coordinator).

NICHD Neonatal Research Steering Committee

Brown University: William Oh, MD; Case Western University: Avroy A. Fanaroff, MD; Duke University: Ronald N. Goldberg, MD; Emory University: Barbara J. Stoll, MD; Indiana University: James A. Lemons, MD; Stanford University: David K. Stevenson, MD; University of Alabama at Birmingham: Waldemar A. Carlo, MD; University of Cincinnati: Edward F. Donovan, MD; University of California-San Diego: Neil N. Finer, MD; University of Miami: Shahnaz Duara, MD; University of Rochester: Dale L. Phelps, MD; University of Texas-Dallas: Abbot R. Laptook, MD; University of Texas-Houston: Jon E. Tyson, MD, MPH; Wake Forest University: T. Michael O'Shea, MD, MPH; Wayne State University: Seetha Shankaran, MD; Yale University: Richard A. Ehrenkranz, MD; and University of Cincinnati (chair): Alan Jobe, MD, PhD.

Data-Coordinating Center: RTI International

W. Kenneth Poole, PhD (principal investigator), and Betty Hastings and Carolyn M. Petrie, MS (coordinators).

Eunice Kennedy Shriver National Institute of Child Health and Human Development

Rosemary D. Higgins, MD, and Linda L. Wright, MD (program scientists), and Elizabeth McClure, MEd (coordinator).

Data Safety and Monitoring Committee

Children's National Medical Center: Gordon Avery, MD; Columbia University: Mary D'Alton, MD; RTI International: W. Kenneth Poole, PhD (ex officio); University of Virginia: John C. Fletcher, PhD (deceased); University of Washington: Christine A. Gleason, MD; and University of Pittsburgh: Carol Redmond, PhD.


This work was supported in part by NICHD grants U10 HD34216, U10 HD27853, U10 HD27871, U10 HD40461, U10 HD40689, U10 HD27856, U10 HD27904, U10 HD40498, U10 HD40521, U01 HD36790, U10 HD21385, U10 HD27880, U10 HD27851, and U10 HD 21373 and GCRCs (General Clinical Research Center) grants from the National Center for Research Resources M01 RR 08084, M01 RR 00125, M01 RR 00750, M01 RR 00070, M01 RR 0039-43, M01RR 00039, and 5 M01 RR00044.


hypoxic-ischemic encephalopathy
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Mental Developmental Index
Gross Motor Functional Classification System
persistent pulmonary hypertension of the newborn
central nervous system
extracorporeal membrane oxygenation


The authors have indicated they have no financial relationships relevant to this article to disclose.

What's Known on This Subject: Term infants with moderate or severe encephalopathy caused by acute perinatal asphyxia are at risk for death and disability in childhood. Hypothermia, either whole-body cooling or selective head cooling, has been found to provide neuroprotection.

What This Study Adds: There are possible adverse effects of cooling in neonates. For the NICHD trial of whole-body cooling for neonatal HIE, we report on outcomes of safety and effectiveness during cooling and at up to 18 months of age.


1. Robertson CMT, Finer NN, Grace MGA. School performance of survivors of neonatal encephalopathy associated with birth asphyxia at term. J Pediatr. 1989;114(5):753–760. [PubMed]
2. Shankaran S, Woldt E, Koepke T, Bedard MP, Nandyal R. Acute neonatal morbidity and long-term central nervous system sequelae of perinatal asphyxia in term infants. Early Hum Dev. 1991;25(2):135–148. [PubMed]
3. Gunn AJ, Gluckman PD, Gunn TR. Selective head cooling in newborn infants after perinatal asphyxia: a safety study. Pediatrics. 1998;102(4 pt 1):885–892. [PubMed]
4. Gluckman PD, Wyatt JS, Azzopardi D, et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicenter randomised trial. Lancet. 2005;365(9460):663–670. [PubMed]
5. Eicher DJ, Wagner CL, Katikaneni LP, et al. Moderate hypothermia in neonatal encephalopathy: efficacy outcomes. Pediatr Neurol. 2005;32(1):11–17. [PubMed]
6. Shankaran S, Laptook AR, Ehrenkranz RA, et al. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N Engl J Med. 2005;353(15):1574–1584. [PubMed]
7. Jacob S, Hunt R, Tarnow-Mordi W, Inder T, Davis P. Cooling for newborns with hypoxic ischemic encephalopathy. Cochrane Database Syst Rev. 2007;4:CD003311. [PubMed]
8. Higgins RD, Tonse RNK, Perlman J, et al. Hypothermia and perinatal asphyxia: executive summary of the National Institute of Child Health and Human Development Workshop. J Pediatr. 2006;148(2):170–175. [PubMed]
9. Blackmon LR, Stark AR, American Academy of Pediatrics. Committee on Fetus and Newborn Hypothermia: a neuroprotective therapy for neonatal hypoxic-ischemic encephalopathy. Pediatrics. 2006;117(3):942–948. [PubMed]
10. Eicher DJ, Wagner CL, Katikaneni LP, et al. Moderate hypothermia in neonatal encephalopathy: safety outcomes. Pediatr Neurol. 2005;32(1):18–24. [PubMed]
11. Debillon T, Daoud P, Durand P, et al. Whole body cooling after perinatal asphyxia: a pilot study in term neonates. Dev Med Child Neurol. 2003;45(1):17–23. [PubMed]
12. Azzopardi D, Robertson NJ, Cowan FM, Rutherford MA, Rampling M, Edwards AD. Pilot study of treatment with whole body hypothermia for neonatal encephalopathy. Pediatrics. 2000;106(4):684–694. [PubMed]
13. Thoresen M, Whitelaw A. Cardiovascular changes during mild therapeutic hypothermia and rewarming in infants with hypoxic ischemic encephalopathy. Pediatrics. 2000;106(1 pt 1):92–99. [PubMed]
14. Sarnat HB, Sarnat MS. Neonatal encephalopathy following fetal distress. Arch Neurol. 1976;33(10):696–675. [PubMed]
15. Bayley N. Bayley Scales of Infant Development II. San Antonio, TX: Psychological Corporation; 1993.
16. Palisano R, Rossenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol. 1997;39(4):214–223. [PubMed]
17. American College of Obstetricians and Gynecologists. Neonatal Encephalopathy and Cerebral Palsy: Defining the Pathogenesis and Pathophysiology. Washington, DC: American College of Obstetricians and Gynecologists; 2003. Task Force on Neonatal Encephalopathy and Cerebral Palsy; American Academy of Pediatrics.
18. Nelson KB. Is it HIE? And why that matters. Acta Paediatr. 2007;96(8):1113–1114. [PubMed]
19. Martín-Ancel A, Garcia-Alix A, Cabañas FGF, Burgueros M, Quero J. Multiple organ involvement in perinatal asphyxia. J Pediatr. 1995;127(5):786–793. [PubMed]
20. Schubert A. Side effects of mild hypothermia. J Neurosurg Anesthesiol. 1995;7(2):139–147. [PubMed]
21. Hypothermia After Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346(8):549–564. [PubMed]N Engl J Med. 2002;346(22):1756. published correction appears in.
22. McIntyre AL, Fergusson DA, Hébert PC, Moher D, Hutchinson JS. Prolonged therapeutic hypothermia after traumatic brain injury in adults. JAMA. 2003;289(22):2992–2999. [PubMed]
23. Gebauer CM, Knuepfer M, Robe-Tillig E, Pulzer F, Vogtmann C. Hemodynamics among neonates with hypoxic-ischemic encephalopathy during whole-body hypothermia and passive rewarming. Pediatrics. 2006;117(3):843–850. [PubMed]
24. Battin MR, Penrice J, Gunn TR, Gunn AJ. Treatment of term infants with head cooling and mild systemic hypothermia (35.0°C and 34.5°C) after perinatal asphyxia. Pediatrics. 2003;111(2):244–251. [PubMed]
25. Bennet L, Dean JM, Wassink G, Gunn AJ. Differential effects of hypothermia on early and late epileptiform events after severe hypoxia in preterm fetal sheep. J Neurophysiol. 2007;97(1):572–578. [PubMed]
26. Perlman JM. Summary proceedings from the Neurology Group on Hypoxic Ischemic Encephalopathy. Pediatrics. 2006;117(3 pt 2):S28–S33. [PubMed]
27. Gunn AJ, Thoresen M. Hypothermic neuroprotection. NeuroRx. 2006;3(2):154–169. [PubMed]
28. Gressens EP. Neuroprotection. Semin Fetal Neonatal Med. 2007;12(4):239–328. [PubMed]